TALA-307

TALA-307 is a preclinical-stage bispecific antibody being developed by Talawar Therapeutics for the treatment of immunologic diseases. The therapeutic candidate is designed to simultaneously target interleukin-13 (IL-13) and a second, currently undisclosed target. By dual-targeting IL-13, a central mediator in Type 2 (Th2) cytokine-driven inflammation, along with a complementary inflammatory pathway, TALA-307 aims to provide enhanced therapeutic efficacy in conditions such as asthma and atopic dermatitis compared to existing monospecific agents. The program is part of Talawar's broader strategy to leverage bispecific antibody architectures to address unmet needs in chronic inflammatory and autoimmune disorders.